Artemisinin reduces cell proliferation and induces apoptosis in neuroblastoma

Oncology Reports

Volumn 32, Issue 3, 2014, Pages 1094-1100

  Zhu, Shunqin ^a,b   Liu, Wanhong ^a,c   Ke, Xiaoxue ^b   Li, Jifu ^b   Hu, Renjian ^b   Cui, Hongjuan ^b   Song, Guanbin ^a  

^a CHONGQING UNIVERSITY   (China)

^b SOUTHWEST UNIVERSITY   (China)

^c CHONGQING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Apoptosis; Artemisinin; Cell cycle; Cell growth; Neuroblastoma; Proliferation

Indexed keywords

ARTEMISININ; ANTINEOPLASTIC AGENT; ARTEMISININ DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARTEMISININS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MICE; MICE, SCID; NEUROBLASTOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923068538     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3323     Document Type: Article

References (39)

1. Brodeur GM: Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3: 203-216, 2003.
2. Beckwith JB and Martin RF: Observations on the histopathology of neuroblastomas. J Pediatr Surg 3: 106-110, 1968.
3. Zhu S, Yan X, Xiang Z, Ding HF and Cui H: Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo. PLoS One 8: e71555, 2013.
4. Li T, Cui ZB, Ke XX, et al: Essential role for p53 and caspase-9 in DNA damaging drug-induced apoptosis in neuroblastoma IMR32 cells. DNA Cell Biol 30: 1045-1050, 2011.
5. Li T, Wang L, Ke XX, et al: DNA-damaging drug-induced apoptosis sensitized by N-myc in neuroblastoma cells. Cell Biol Int 36: 331-337, 2012.
6. Askin FB and Perlman EJ: Neuroblastoma and peripheral neuroectodermal tumors. Am J Clin Pathol 109: S23-S30, 1998.
7. Shah S and Ravindranath Y: Neuroblastoma. Indian J Pediat 65: 691-705, 1998. (Pubitemid 28475727)
8. Bessho F: Incidence of neuroblastoma. Lancet 353: 70, 1999.
9. Sridhar S, Al-Moallem B, Kamal H, Terrile M and Stallings RL: New insights into the genetics of neuroblastoma. Mol Diagn Ther 17: 63-69, 2013.
10. Crespo-Ortiz MP and Wei MQ: Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anti-cancer drug. J Biomed Biotechnol 2012: 247597, 2012.
11. Newman DJ and Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461-477, 2007. (Pubitemid 46595760)
12. Zhang YJ, Gallis B, Taya M, Wang S, Ho RJ and Sasaki T: pH-responsive artemisinin derivatives and lipid nanoparticle formulations inhibit growth of breast cancer cells in vitro and induce down-regulation of HER family members. PloS One 8: e59086, 2013.
13. Miller LH and Su X: Artemisinin: discovery from the Chinese herbal garden. Cell 146: 855-858, 2011.
14. Sundar SN, Marconett CN, Doan VB, Willoughby JA Sr and Firestone GL: Artemisinin selectively decreases functional levels of estrogen receptor-alpha and ablates estrogen-induced proliferation in human breast cancer cells. Carcinogenesis 29: 2252-2258, 2008.
15. Duffy PE and Mutabingwa TK: Drug combinations for malaria: time to ACT? Lancet 363: 3-4, 2004. (Pubitemid 38076914)
16. Willoughby JA Sr, Sundar SN, Cheung M, Tin AS, Modiano J and Firestone GL: Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 284: 2203-2213, 2009.
17. Lai HC, Singh NP and Sasaki T: Development of artemisinin compounds for cancer treatment. Invest New Drugs 31: 230-246, 2013.
18. Tin AS, Sundar SN, Tran KQ, Park AH, Poindexter KM and Firestone GL: Antiproliferative effects of artemisinin on human breast cancer cells requires the downregulated expression of the E2F1 transcription factor and loss of E2F1-target cell cycle genes. Anticancer Drugs 23: 370-379, 2012.
19. Weifeng T, Feng S, Xiangji L, et al: Artemisinin inhibits in vitro and in vivo invasion and metastasis of human hepatocellular carcinoma cells. Phytomedicine 18: 158-162, 2011.
20. Reungpatthanaphong P and Mankhetkorn S: Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 25: 1555-1561, 2002. (Pubitemid 39663669)
21. Yamachika E, Habte T and Oda D: Artemisinin: an alternative treatment for oral squamous cell carcinoma. Anticancer Res 24: 2153-2160, 2004. (Pubitemid 39166289)
22. Cui H, Schroering A and Ding HF: p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells. Mol Cancer Ther 1: 679-686, 2002.
23. Lim S and Kaldis P: Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 140: 3079-3093, 2013.
24. Lee IH and Finkel T: Metabolic regulation of the cell cycle. Curr Opin Cell Biol 25: 724-729, 2013.
25. Agrez M, Kovach J and Lieber M: Cell aggregates in the soft agar. human tumour stem-cell assay. Br J Cancer 46: 880, 1982.
26. Youns M, Efferth T, Reichling J, Fellenberg K, Bauer A and Hoheisel JD: Gene expression profiling identifies novel key players involved in the cytotoxic effect of Artesunate on pancreatic cancer cells. Biochem Pharmacol 78: 273-283, 2009.
27. Li S, Xue F, Cheng Z, et al: Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. Int J Hematol 90: 513-521, 2009.
28. Zeng Y, Ni X, Meng WT, Wen Q and Jia YQ: Inhibitive effect of artesunate on human lymphoblastic leukemia/lymphoma cells. Sichuan Da Xue Xue Bao Yi Xue Ban 40: 1038-1043, 2009 (In Chinese).
29. Zhou HJ, Wang WQ, Wu GD, Lee J and Li A: Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol 47: 131-138, 2007. (Pubitemid 47095451)
30. Li LN, Zhang HD, Yuan SJ, Yang DX, Wang L and Sun ZX: Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. Eur J Pharmacol 588: 1-8, 2008.
31. Rasheed SAK, Efferth T, Asangani IA and Allgayer H: First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int J Cancer 127: 1475-1485, 2010.
32. Chaturvedi D, Goswami A, Saikia PP, Barua NC and Rao PG: Artemisinin and its derivatives: a novel class of anti-malarial and anticancer agents. Chem Soc Rev 39: 435-454, 2010.
33. Firestone GL and Sundar SN: Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med 11: e32, 2009.
34. Efferth T, Sauerbrey A, Olbrich A, et al: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 64: 382-394, 2003. (Pubitemid 36910002)
35. Xu Q, Li ZX, Peng HQ, et al: Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo. J Zhejiang Univ Sci B 12: 247-255, 2011.
36. Noori S, Hassan ZM and Farsam V: Artemisinin as a Chinese medicine, selectively induces apoptosis in pancreatic tumor cell line. Chin J Integr Med: Jun 15, 2013 (Epub ahead of print).
37. Xiao F, Gao W, Wang X and Chen T: Amplification activation loop between caspase-8 and -9 dominates artemisinin-induced apoptosis of ASTC-a-1 cells. Apoptosis 17: 600-611, 2012.
38. Hou JM, Wang DS, Zhang RW and Wang H: Experimental therapy of hepatoma with artemisinin and its derivatives: In vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res 14: 5519-5530, 2008.
39. Gao W, Xiao F, Wang X and Chen T: Artemisinin induces A549 cell apoptosis dominantly via a reactive oxygen species-mediated amplification activation loop among caspase-9, -8 and -3. Apoptosis 18: 1201-1213, 2013.